Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer
Rhea-AI Summary
Radiopharm Theranostics (ASX:RADX) received Bellberry Human Research Ethics Committee approval on November 18, 2025 to start a First‑In‑Human Phase 1 trial of RAD 402, an anti‑KLK3 monoclonal antibody radiolabelled with 161Tb for metastatic or locally advanced prostate cancer.
Preclinical biodistribution in mouse xenografts showed strong tumour targeting, limited bone and marrow uptake, and hepatic excretion. Radiopharm has supply agreements with Terthera (2022) for 161Tb production and Cyclotek (2025) for radiolabelling RAD 402, supporting trial initiation.
Positive
- HREC approval granted to start Phase 1 trial (Nov 18, 2025)
- Preclinical strong tumour targeting in mouse xenografts
- Signed supply agreements with Terthera (2022) and Cyclotek (2025)
Negative
- RAD 402 is at Phase 1 first‑in‑human stage; clinical efficacy not yet established
- Preclinical data limited to mouse xenografts, not clinical outcomes
News Market Reaction 3 Alerts
On the day this news was published, RADX declined 4.76%, reflecting a moderate negative market reaction. Argus tracked a peak move of +9.0% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $36M at that time.
Data tracked by StockTitan Argus on the day of publication.
RAD 402 is a humanized IgG1 internalized by prostate cells, binding KLK3 with high affinity
Tb-161 antitumor activity driven by the dual emission of beta particles and Auger electrons
SYDNEY, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has been granted Bellberry Human Research Ethics Committee (HREC) approval in Australia to initiate its First-In-Human (FIH) Phase 1 clinical trial of its Kallikrein Related Peptidase 3 (KLK3)-targeting radiotherapeutic, RAD 402, for the treatment of metastatic or locally advanced prostate cancer.
RAD 402 is an anti-KLK3 monoclonal antibody radiolabelled with the radionuclide 161Tb for the treatment of prostate cancer. Prostate Specific Antigen (PSA) is a widely used biomarker to detect prostate cancer and is encoded by the KLK3 gene. KLK3 is expressed in the prostate along with most adenocarcinomas of the prostate including their metastases.
Previous comprehensive preclinical proof-of-concept Biodistribution studies of RAD 402 in mouse xenografts showed strong tumour targeting, limited bone and marrow uptake, and a hepatic excretion profile consistent with expectations for a monoclonal antibody. Radiopharm has signed in 2022 a supply agreement with Terthera for the production of Tb161 and in 2025 with Cyclotek for radiolabeling RAD402 with 161Tb, supporting the initiation of the Phase 1 FiH trial of RAD 402.
“Receiving HREC approval marks a key milestone for Radiopharm and for patients in need of safer, more effective new treatments for prostate cancer,” said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. “This clearance enables us to advance RAD 402 into our first-in-human Phase 1 clinical trial, which, to my knowledge, is the first company-sponsored therapeutic trial using 161Tb. We are highly encouraged by RAD 402’s potential antitumor activity, driven by the dual emission of beta particles and Auger electrons from Tb-161. Targeting KLK3 in advanced prostate cancer represents a novel and promising mechanism of action. The strength of our preclinical data, combined with regulatory endorsement, underscores RAD 402’s first-in-class potential.”
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and four Phase 1 trials in a variety of solid tumor cancers, including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com.
Authorised on behalf of the Radiopharm Theranostics board of directors by Chairman Paul Hopper.
For more information:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com
Anne Marie Fields
Precision AQ (Formerly Stern IR)
E: annemarie.fields@precisionaq.com
Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com
Media
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au
FAQ
What did Radiopharm (RADX) announce on November 18, 2025 about RAD 402?
What is RAD 402 and how does it work in prostate cancer?
What preclinical results support Radiopharm's RAD 402 trial (RADX)?
Who supplies the 161Tb and radiolabelling for RAD 402 (RADX)?
What patient population will the RAD 402 Phase 1 trial target?
